Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
NORCROSS, Ga., March 05, 2018 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced March 26, 2018 is the record date for the 2018 Annual Meeting of Stockholders to be held on May 22, 2018 in Atlanta, GA.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin’s lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Contacts:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected].
